新冠感染对法国重症肌无力队列的影响
CO-MY-COVID登记研究为法国多中心回顾性观察队列,纳入3558例注册重症肌无力患者中34例(0.96%)新冠感染者,评估临床特征与新冠严重程度相关因素。结果显示仅感染前MGFA分级≥IV与新冠重症相关(p=0.004),免疫抑制药物与糖皮质激素不增加不良结局风险。
要点
- 仅感染前MGFA分级≥IV与新冠重症相关,性别、MG病程及MGFA≤IIIb级无关联
- 免疫抑制药物及糖皮质激素治疗对新冠严重程度无独立影响
核心结论
- 新冠对多数重症肌无力患者影响有限,免疫抑制治疗不是不良结局的危险因素。
- 感染前高MGFA分级(≥IV)患者发生新冠重症的风险升高。
研究设计与样本
- CO-MY-COVID登记为多中心、回顾性、观察性队列研究,在FILNEMUS网络神经肌肉转诊中心与综合医院开展(2020年3月1日至6月8日)。
- 纳入确诊或高度疑似新冠的重症肌无力患者,新冠诊断依据鼻咽拭子PCR、SARS-CoV-2血清学、胸部CT或典型症状。
- 法国罕见病数据库中注册的3558例重症肌无力患者中,34例(0.96%)患新冠。
主要发现
- 新冠发病平均年龄55.0±19.9岁,平均MG病程8.5±8.5年。
- 研究期末28例康复、1例仍患病、5例死亡。
- 仅感染前MGFA分级≥IV与新冠重症相关(p=0.004)。
- 性别、MG病程及MGFA≤IIIb级与新冠重症无关联。
- MG治疗类型对新冠严重程度无独立影响。
关键数值与推荐
- 新冠严重程度按处理/治疗地点划分:居家、住院内科病房或重症监护室。
临床怎么用
- 多数重症肌无力患者感染新冠后影响有限,无需因免疫抑制或激素治疗而常规调整方案。
- 对感染前MGFA分级≥IV的患者应加强监测,警惕新冠重症风险。
局限性
- 为回顾性观察性登记研究,样本量小(34例新冠患者),事件数有限。
- 原文未报告其他局限性信息。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To describe the clinical characteristics and outcomes of coronavirus disease 2019 (COVID-19) among patients with myasthenia gravis (MG) and identify factors associated with COVID-19 severity in patients with MG. METHODS: The CO-MY-COVID registry was a multicenter, retrospective, observational cohort study conducted in neuromuscular referral centers and general hospitals of the FILNEMUS (Filière Neuromusculaire) network (between March 1, 2020, and June 8, 2020), including patients with MG with a confirmed or highly suspected diagnosis of COVID-19. COVID-19 was diagnosed based on a PCR test from a nasopharyngeal swab or severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) serology, thoracic CT scan, or typical symptoms. The main outcome was COVID-19 severity based on location of treatment/management (home, hospitalized in a medical unit, or in an intensive care unit). We collected information on demographic variables, general history, and risk factors for severe COVID-19. Multivariate ordinal regression models were used to identify factors associated with severe COVID-19 outcomes. RESULTS: Among 3,558 patients with MG registered in the French database for rare disorders, 34 (0.96%) had COVID-19. The mean age at COVID-19 onset was 55.0 ± 19.9 years (mean MG duration: 8.5 ± 8.5 years). By the end of the study period, 28 patients recovered from COVID-19, 1 remained affected, and 5 died. Only high Myasthenia Gravis Foundation of America (MGFA) class (≥IV) before COVID-19 was associated with severe COVID-19 (p = 0.004); factors that were not associated included sex, MG duration, and medium MGFA classes (≤IIIb). The type of MG treatment had no independent effect on COVID-19 severity. CONCLUSIONS: This registry-based cohort study shows that COVID-19 had a limited effect on most patients, and immunosuppressive medications and corticosteroids used for MG management are not risk factors for poorer outcomes. However, the risk of severe COVID-19 is elevated in patients with high MGFA classes (odds ratio, 102.6 [4.4-2,371.9]). These results are important for establishing evidence-based guidelines for the management of patients with MG during the COVID-19 pandemic.
引用
- Solé G, Mathis S, Friedman D, et al. Impact of Coronavirus Disease 2019 in a French Cohort of Myasthenia Gravis. Neurology. 2021. PMID: 33568541. doi:10.1212/WNL.0000000000011669
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。